Drug Trial Radar · NCT05642507
Phase Ib/IIa Trial With AC01 in Patients With HFrEF
Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Feb 23, 2023
Primary completion
Oct 27, 2025
Study completion Oct 27, 2025
Sponsor
- Lead sponsor
- AnaCardio ABIndustry
- Sponsor type
- Industry
- First posted
- Dec 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled two-part study with a multiple escalating dose phase followed by a cohort expansion phase to assess safety, tolerability, pharmacokinetics and pharmacodynamics of AC01 in patients with heart failure with reduced ejection fraction (HFrEF).
Conditions
- Heart Failure With Reduced Ejection Fraction
Interventions
AC01Drug
AC01 Minitablets
Placebo MinitabletsDrug
Placebo Minitablets are indistinguishable from active AC01 Minitablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability: Adverse Events (AEs)Time frame: From first dose of study drug up to end of follow up (up to 12 days during dose escalation phase and up to 35 days during cohort expansion phase).
- Safety and tolerability: Vital signs.Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion)
- Safety and tolerability: Vital signs.Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion).
- Safety and tolerability: Vital signs.Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion).
- Safety and tolerability: Electrocardiogram (ECG).Time frame: From first dose of study drug up to end of follow up (up to 12 days during dose escalation phase and up to 35 days during cohort expansion phase).
- Safety and tolerability: Electrocardiogram (ECG).Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion).
- Safety and tolerability: Clinical laboratory evaluations.Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion).
- Safety and tolerability: Clinical laboratory evaluations.Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion).
- Safety and tolerability: Clinical laboratory evaluations.Time frame: Baseline and end-of-treatment (Day 7 during the dose escalation and Day 28 during cohort expansion).
Locations
14 sites in 4 countries. Site status is shown where the registry gives one.
Spedali Civilia di Brescia
Brescia, Italy
Azienda Sanitaria Universitaria Integrata
Trieste, Italy
Amsterdam University Medical Centre
Amsterdam, Netherlands
University Medical Centre Groningen/ICON
Groningen, Netherlands
Maastricht Heart and Vascular Center
Maastricht, Netherlands
Erasmus Medical Centre
Rotterdam, Netherlands
University Medical Center
Utrecht, Netherlands
Sahlgrenska University Hospital
Gothenburg, Sweden
Skånes Universitetssjukhus Lund
Lund, Sweden
Karolinska University Hospital
Stockholm, Sweden
Ninewells Hospital and Medical School
Dundee, United Kingdom
University of Glasgow, Institute of Cardiovascular & Medical Sciences
Glasgow, United Kingdom
Golden Jubilee National Hospital
Glasgow, United Kingdom
King's College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.